TIDMSBS
RNS Number : 8695J
Source BioScience PLC
14 September 2016
FORM 8 (DD)
PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON
ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF
DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Mr Tim Metcalfe (Finance Director of Source BioScience
plc)
---------------------------------------------------------- ----------------------------------------------------------
(b) Owner or controller of interests and short positions N/A
disclosed, if different from 1(a):
The naming of nominee or vehicle companies is
insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
---------------------------------------------------------- ----------------------------------------------------------
(c) Name of offeror/offeree in relation to whose relevant Source BioScience plc
securities this form relates:
Use a separate form for each offeror/offeree
---------------------------------------------------------- ----------------------------------------------------------
(d) Status of person making the disclosure: Person acting in concert with the offeree
e.g. offeror, offeree, person acting in concert with the
offeror/offeree (specify name of
offeror/offeree)
---------------------------------------------------------- ----------------------------------------------------------
(e) Date dealing undertaken: 13 September 2016
---------------------------------------------------------- ----------------------------------------------------------
(f) In addition to the company in 1(c) above, is the N/A
discloser making disclosures in respect
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
---------------------------------------------------------- ----------------------------------------------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing
Class of relevant security:
------------------------------------------------------------------------------- -------------------------------------
Interests Short positions
------------------------------------------------------------------------------- ----------------- ------------------
Number % Number %
------------------------------------------------------------------------------- ---------- ----- ------------- ---
(1) Relevant securities owned and/or controlled: 1,606,154 0.4% nil -
------------------------------------------------------------------------------- ---------- ----- ------------- ---
(2) Cash-settled derivatives: nil - nil -
------------------------------------------------------------------------------- ---------- ----- ------------- ---
(3) Stock-settled derivatives (including options) and agreements to nil - nil -
purchase/sell:
------------------------------------------------------------------------------- ---------- ----- ------------- ---
TOTAL: 1,606,154 0.4% nil -
------------------------------------------------------------------------------- ---------- ----- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists: Ordinary shares of 2 pence each
--------------------------------------------------------------------------- --------------------------------
Details, including nature of the rights concerned and relevant
percentages:
Director Maximum Date of First Last exercisable Option
number Grant exercisable date price
of Ordinary date (pence)
Shares
awarded
------------- ------------- -------- ------------- ----------------- ---------
Tim Metcalfe 2,769,231 25 Jun 15 Mar 25 Jun nil
2015 2019 2025
------------- ------------- -------- ------------- ----------------- ---------
3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
(i) Party to an offer or person acting in concert (except for a
principal trader in the same group as a connected adviser)
Class of relevant security Purchase/sale Number of securities Price per unit
--------------------------- -------------- --------------------- ---------------
n/a n/a n/a n/a
--------------------------- -------------- --------------------- ---------------
(ii) Principal trader where the sole reason for the connection
is that the principal trader is in the same group as a connected
adviser
Class of relevant Purchases/ sales Total number of Highest price per unit Lowest price per unit
security securities paid/received paid/received
----------------------- ----------------- ------------------------ ----------------------- -----------------------
n/a n/a n/a n/a n/a
----------------------- ----------------- ------------------------ ----------------------- -----------------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
------------------------- -------------------- ------------------------- ------------------------- ---------------
n/a n/a n/a n/a n/a
------------------------- -------------------- ------------------------- ------------------------- ---------------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
------------- ------------- ------------- ------------- -------------- ------------- ------------ -------------
n/a n/a n/a n/a n/a n/a n/a n/a
------------- ------------- ------------- ------------- -------------- ------------- ------------ -------------
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
----------------------- -------------------- ----------------------- --------------------- -----------------------
Ordinary shares of 2 Share options Exercised 1,606,154 Nil
pence each
----------------------- -------------------- ----------------------- --------------------- -----------------------
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
--------------------------- ------------------------------- -------- -------------------------------
n/a n/a n/a n/a
--------------------------- ------------------------------- -------- -------------------------------
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer or person acting in concert making the
disclosure and any other person:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
--------------------------------------------------------------------------------------------
None
--------------------------------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer or person acting in concert making the disclosure and any other person relating
to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
----------------------------------------------------------------------------------------------
None
----------------------------------------------------------------------------------------------
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
------------------------------------- ---
Supplemental Form 8 (SBL) NO
------------------------------------- ---
Date of disclosure: 14 September 2016
--------------------- -----------------------------
Contact name: Nick Ash (Company Secretary)
--------------------- -----------------------------
Telephone number: +44 (0) 115 973 9010
--------------------- -----------------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's dealing disclosure
requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCAKQDNPBKDFCD
(END) Dow Jones Newswires
September 14, 2016 11:38 ET (15:38 GMT)
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Nov 2023 to Nov 2024
